Jacobs Levy Equity Management Inc. Has $2.26 Million Stock Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Jacobs Levy Equity Management Inc. lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 67.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 470,726 shares of the biopharmaceutical company's stock after selling 959,807 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 0.81% of Vanda Pharmaceuticals worth $2,255,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. Deutsche Bank AG lifted its stake in shares of Vanda Pharmaceuticals by 54.6% in the 4th quarter. Deutsche Bank AG now owns 70,169 shares of the biopharmaceutical company's stock valued at $336,000 after purchasing an additional 24,792 shares during the period. Cubist Systematic Strategies LLC lifted its stake in shares of Vanda Pharmaceuticals by 9.6% in the 4th quarter. Cubist Systematic Strategies LLC now owns 108,835 shares of the biopharmaceutical company's stock valued at $521,000 after purchasing an additional 9,493 shares during the period. Bank of America Corp DE lifted its stake in shares of Vanda Pharmaceuticals by 28.8% in the 4th quarter. Bank of America Corp DE now owns 128,336 shares of the biopharmaceutical company's stock valued at $615,000 after purchasing an additional 28,659 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Vanda Pharmaceuticals by 16.2% in the 4th quarter. BNP Paribas Financial Markets now owns 72,312 shares of the biopharmaceutical company's stock valued at $346,000 after purchasing an additional 10,074 shares during the period. Finally, Schonfeld Strategic Advisors LLC acquired a new position in shares of Vanda Pharmaceuticals in the 4th quarter valued at $1,296,000. Institutional investors and hedge funds own 88.14% of the company's stock.

Analyst Ratings Changes

VNDA has been the topic of a number of analyst reports. StockNews.com initiated coverage on Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They issued a "hold" rating on the stock. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 7th.

Vanda Pharmaceuticals Stock Up 0.3%

VNDA opened at $3.93 on Friday. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $6.75. The company has a fifty day simple moving average of $4.44 and a 200 day simple moving average of $4.63. The stock has a market cap of $231.61 million, a P/E ratio of -12.28 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. On average, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $5.02 per share, for a total transaction of $50,200.00. Following the acquisition, the chief executive officer now owns 2,285,731 shares in the company, valued at approximately $11,474,369.62. This trade represents a 0.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last 90 days, insiders bought 32,000 shares of company stock worth $151,180. Corporate insiders own 10.00% of the company's stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.

Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.